Novel paradigm-shifting vaccines with emphasis on cellular immunity
Belyntic has raised $811K in total funding. The most recent round was Non-equity Assistance. The last funding was announced in November 2021.
Belyntic's investors include HTGF (High-Tech Gruenderfonds), Federal Ministry for Economic Affairs and Energy (BMWi), EXIST, Investitionsbank Berlin, Till Knorr.
Belyntic is headquartered in Berlin, Germany.
Novel paradigm-shifting vaccines with emphasis on cellular immunity
Belyntic is at the Non-equity Assistance stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Belyntic — Funding & Investors." VCBacked, November 8, 2021, https://www.vcbacked.co/company/belyntic. Accessed August 14, 2026.
VCBacked. (2021). Belyntic — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/belyntic
{{cite web |title=Belyntic — Funding & Investors |url=https://www.vcbacked.co/company/belyntic |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated